Industry to pay for UK agency fees hike as full regulatory costs recovery begins
This article was originally published in Clinica
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) must now, for the first time, achieve full cost recovery for medical device regulatory activities, in line with what has been the case for some considerable time in the pharmaceutical sector. And medical device manufacturers will be meeting those costs.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.